



Nanomix Awarded U.S. Patent for Nanoelectronic Electrochemical Test Device

Emeryville, CA (March 7, 2017) - Nanomix Inc., (Nanomix), a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, has been awarded a US Patent related to its Nanomix eLab[®] system.

US Patent 9,588,077 entitled “Nanoelectronic Electrochemical Test Device” was issued on March 7, 2017.

About the Nanomix eLab System

The Nanomix eLab[®] system is comprised of a mobile, handheld diagnostic device and a disposable microfluidics test cartridge. The device is simple to operate via an intuitive user interface on a color touch screen and incorporates a proprietary nano-biosensor for high quality, reliable performance. The single-use disposable test cartridge uses the patient’s whole blood, without sample preparation. All test functions are controlled and automatically processed by the device. The robust system design supports use in almost any setting, inside or outside of the traditional laboratory environment. The eLab device is Bluetooth enabled for rapid communication of results. Internal testing by Nanomix scientists, their clinical partners, and other outside evaluators has shown the eLab to produce results equivalent to those produced by expensive central laboratory testing systems.

For more information, visit: <http://www.nano.com>

Contact:

Joy Bissell

jbissell@nano.com

Nanomix, Inc.

1440 Stanford Ave.

Emeryville, CA 94608

Phone: 1-510-428-5300